Ian Sanne to RNA, Viral
This is a "connection" page, showing publications Ian Sanne has written about RNA, Viral.
Connection Strength
0,653
-
Evaluation of GeneXpert and advanced biological laboratories UltraGene HCV diagnostic detection and performance against Roche real time PCR in Myanmar. J Clin Virol. 2024 04; 171:105653.
Score: 0,205
-
Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses. Int J Tuberc Lung Dis. 2012 Oct; 16(10):1358-64.
Score: 0,092
-
Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011 Jan 01; 52(1):128-37.
Score: 0,083
-
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003 Jan 01; 32(1):18-29.
Score: 0,047
-
Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. J Viral Hepat. 2022 06; 29(6):474-486.
Score: 0,045
-
Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response. J Immunol Methods. 2021 09; 496:113096.
Score: 0,043
-
Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. AIDS. 2020 04 01; 34(5):681-686.
Score: 0,039
-
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
Score: 0,022
-
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One. 2010 Jul 01; 5(7):e11416.
Score: 0,020
-
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010 Apr 01; 50(7):1041-52.
Score: 0,020
-
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004 Jul 15; 190(2):280-4.
Score: 0,013
-
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003 Dec 05; 17(18):2603-14.
Score: 0,013
-
T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment. AIDS. 2003 May 23; 17(8):1145-9.
Score: 0,012